Harvard Bioscience (NASDAQ:HBIO) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.57 and traded as high as $0.60. Harvard Bioscience shares last traded at $0.5655, with a volume of 204,569 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on HBIO shares. Zacks Research raised shares of Harvard Bioscience to a “hold” rating in a report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a research report on Monday, November 17th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $2.00.

Harvard Bioscience Trading Down 4.3%

The firm has a market capitalization of $25.29 million, a price-to-earnings ratio of -0.46 and a beta of 1.51. The firm’s 50-day moving average is $0.60 and its 200 day moving average is $0.57.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of HBIO. Bank of America Corp DE grew its position in shares of Harvard Bioscience by 44.4% in the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 11,948 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Harvard Bioscience by 7.8% in the first quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock worth $606,000 after acquiring an additional 78,276 shares during the period. Strs Ohio bought a new stake in Harvard Bioscience in the first quarter valued at approximately $117,000. Marshall Wace LLP acquired a new stake in Harvard Bioscience during the 2nd quarter valued at approximately $61,000. Finally, Jane Street Group LLC raised its holdings in Harvard Bioscience by 491.9% during the 2nd quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 58,785 shares during the last quarter. 80.87% of the stock is owned by institutional investors and hedge funds.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.